FDA To Weigh Public Input On Biosimilars Program

By Derek Hawkins · December 6, 2011, 7:29 PM EST

The U.S. Food and Drug Administration said Monday it would hold a public hearing to seek stakeholder input on the agency's proposed user fee program for biosimilar biological products, a move...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Proposal

Recent Articles By Derek

December 03, 2012
Republicans Say HHS Is Biased Against Fracking
October 19, 2012
Powerful House, Senate Panels Set For Election Year Shake-Up
February 21, 2012
Mylan Settles Defamation Suits Against Pittsburgh Paper
February 08, 2012
Continental Ducks Coverage For $198M Anthem Settlement
January 24, 2012
Canada, Novartis Issue Warning On Blood Pressure Drugs
January 20, 2012
Health Group Of The Year: Covington & Burling
January 10, 2012
UCLA Still Silent On Data Breach Class Action
January 09, 2012
Novartis Issues $120M Drug Recall, Plant Suspension
January 03, 2012
FDA Seeks To Streamline Medical Device Approvals
December 12, 2011
Medtronic Investors Win Cert. In Off-Label Marketing Case